## Werner Weitschies

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8852949/publications.pdf

Version: 2024-02-01

225 papers 15,361 citations

25014 57 h-index 118 g-index

235 all docs 235 docs citations

times ranked

235

13409 citing authors

#	Article	IF	Citations
1	Increasing the Robustness of Biopharmaceutical Precipitation Assays – Part II: Recommendations on the use of FaSSIF. Journal of Pharmaceutical Sciences, 2022, 111, 155-163.	1.6	3
2	The effect of buffer species on biorelevant dissolution and precipitation assays – Comparison of phosphate and bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 171, 90-101.	2.0	15
3	The challenges of drug delivery to the esophagus and how to overcome them. Expert Opinion on Drug Delivery, 2022, 19, 119-131.	2.4	6
4	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics, 2022, 14, 801.	2.0	4
5	An Advanced Bioreactor Simulating Dynamic Physiological Conditions in the Human Ascending Colon: MimiCol3. Pharmaceutics, 2022, 14, 1049.	2.0	1
6	Development of a Hot-Melt-Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns. Pharmaceutics, 2022, 14, 1229.	2.0	3
7	Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial. Pharmaceutics, 2022, 14, 1242.	2.0	5
8	Characterization of gastrointestinal transit and luminal conditions in pigs using a telemetric motility capsule. European Journal of Pharmaceutical Sciences, 2021, 156, 105627.	1.9	31
9	InÂVitro and InÂVivo Evaluation of 3D Printed Capsules with Pressure Triggered Release Mechanism for Oral Peptide Delivery. Journal of Pharmaceutical Sciences, 2021, 110, 228-238.	1.6	19
10	3D Printing of Mini Tablets for Pediatric Use. Pharmaceuticals, 2021, 14, 143.	1.7	29
11	Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections. Journal of Pharmaceutical Sciences, 2021, 110, 1302-1309.	1.6	1
12	Establishment of a Dissolution Test System for the Biorelevant Characterization of Esophageal Applied Dosage Forms. Journal of Pharmaceutical Sciences, 2021, , .	1.6	1
13	Functionality and Acceptance of the EsoCap System—A Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study. Pharmaceutics, 2021, 13, 828.	2.0	4
14	Mimicking the dynamic Colonic microbiota in vitro to gain a better understanding on the in vivo metabolism of xenobiotics: Degradation of sulfasalazine. International Journal of Pharmaceutics, 2021, 603, 120704.	2.6	5
15	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	1.9	137
16	Supercritical fluid extraction–supercritical fluid chromatography of saliva: Singleâ€quadrupole mass spectrometry monitoring of caffeine for gastric emptying studies â€. Journal of Separation Science, 2021, 44, 3700-3716.	1.3	3
17	The EyeFlowCell: Development of a 3D-Printed Dissolution Test Setup for Intravitreal Dosage Forms. Pharmaceutics, 2021, 13, 1394.	2.0	8
18	Ingestible devices for studying the gastrointestinal physiology and their application in oral biopharmaceutics. Advanced Drug Delivery Reviews, 2021, 176, 113853.	6.6	18

#	Article	IF	Citations
19	Effect of obesity on gastrointestinal transit, pressure and pH using a wireless motility capsule. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 167, 1-8.	2.0	16
20	Development of a furosemide-containing expandable system for gastric retention. Journal of Controlled Release, 2021, 338, 105-118.	4.8	4
21	Influence of the geometry of 3D printed solid oral dosage forms on their swallowability. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 167, 65-72.	2.0	12
22	The Effect of Capsule-in-Capsule Combinations on In Vivo Disintegration in Human Volunteers: A Combined Imaging and Salivary Tracer Study. Pharmaceutics, 2021, 13, 2002.	2.0	10
23	Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir. Pharmaceutics, 2020, 12, 670.	2.0	15
24	The EsoCap-system â€" An innovative platform to drug targeting in the esophagus. Journal of Controlled Release, 2020, 327, 1-7.	4.8	16
25	Abomasal emptying rate of diarrhoeic and healthy suckling calves fed with oral rehydration solutions. Journal of Animal Physiology and Animal Nutrition, 2020, 104, 462-469.	1.0	6
26	Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 151, 9-17.	2.0	18
27	In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms. Pharmaceutics, 2019, 11, 416.	2.0	39
28	Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model. Molecular Pharmaceutics, 2019, 16, 3938-3947.	2.3	17
29	Design and characterization of a novel 3D printed pressure-controlled drug delivery system. European Journal of Pharmaceutical Sciences, 2019, 140, 105060.	1.9	28
30	Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach. Molecular Pharmaceutics, 2019, 16, 4651-4660.	2.3	28
31	In vivo characterization of enTRinsicâ,,¢ drug delivery technology capsule after intake in fed state: A cross-validation approach using salivary tracer technique in comparison to MRI. Journal of Controlled Release, 2019, 313, 24-32.	4.8	14
32	Development of oral foams for topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology, 2019, 50, 287-292.	1.4	6
33	Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 221-230.	2.0	42
34	Application of an automated small-scale in vitro transfer model to predict in vivo precipitation inhibition. International Journal of Pharmaceutics, 2019, 565, 458-471.	2.6	4
35	INFOGEST static in vitro simulation of gastrointestinal food digestion. Nature Protocols, 2019, 14, 991-1014.	5.5	1,873
36	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	1.9	146

#	Article	IF	Citations
37	Combined Application of MRI and the Salivary Tracer Technique to Determine the <i>in Vivo</i> Disintegration Time of Immediate Release Formulation Administered to Healthy, Fasted Subjects. Molecular Pharmaceutics, 2019, 16, 1782-1786.	2.3	22
38	Comparison of In Vitro and In Vivo Results Using the GastroDuo and the Salivary Tracer Technique: Immediate Release Dosage Forms under Fasting Conditions. Pharmaceutics, 2019, 11, 659.	2.0	16
39	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	2.0	91
40	Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles. International Journal of Pharmaceutics, 2019, 556, 150-158.	2.6	9
41	Characterization of the gastrointestinal transit and disintegration behavior of floating and sinking acid-resistant capsules using a novel MRI labeling technique. European Journal of Pharmaceutical Sciences, 2019, 129, 163-172.	1.9	26
42	Interindividual and intraindividual variability of fasted state gastric fluid volume and gastric emptying of water. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 309-317.	2.0	86
43	Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 270-278.	2.0	17
44	Immediate Release 3D-Printed Tablets Produced Via Fused Deposition Modeling of a Thermo-Sensitive Drug. Pharmaceutical Research, 2018, 35, 124.	1.7	115
45	Gastric Emptying and Small Bowel Water Content after Administration of Grapefruit Juice Compared to Water and Isocaloric Solutions of Glucose and Fructose: A Four-Way Crossover MRI Pilot Study in Healthy Subjects. Molecular Pharmaceutics, 2018, 15, 548-559.	2.3	58
46	Low dose caffeine as a salivary tracer for the determination of gastric water emptying in fed and fasted state: A MRI validation study. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 443-452.	2.0	23
47	The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference. European Journal of Pharmaceutical Sciences, 2018, 111, 153-157.	1.9	23
48	Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after Lipopolysaccharide Challenge in Pigs. International Journal of Molecular Sciences, 2018, 19, 3009.	1.8	11
49	Development of a dual extrusion printing technique for an acid- and thermo-labile drug. European Journal of Pharmaceutical Sciences, 2018, 123, 191-198.	1.9	42
50	7.1 T MRI and T2 mapping of the human and porcine vitreous body post mortem. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 82-91.	2.0	8
51	In-line derivative spectroscopy as a promising application to a small-scale <i>in vitro</i> transfer model in biorelevant supersaturation and precipitation testing. Journal of Pharmacy and Pharmacology, 2018, 70, 1315-1323.	1.2	14
52	Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms. AAPS PharmSciTech, 2018, 19, 2843-2850.	1.5	14
53	Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5Âyears. European Radiology, 2017, 27, 772-777.	2.3	36
54	An overview of intestinal wafers for oral drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 135-144.	2.0	13

#	Article	IF	CITATIONS
55	Assessment of different polymers and drug loads for fused deposition modeling of drug loaded implants. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 84-93.	2.0	139
56	Preparation and characterization of gastrointestinal wafer formulations. International Journal of Pharmaceutics, 2017, 522, 165-171.	2.6	5
57	Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of <i>in Vitro</i> Predictive Tools. Molecular Pharmaceutics, 2017, 14, 4220-4232.	2.3	28
58	Muscle Injury After Intramuscular Administration of Diclofenac: A Case Report Supported by Magnetic Resonance Imaging. Drug Safety - Case Reports, 2017, 4, 7.	0.9	8
59	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	2.6	81
60	Effect of Coadministered Water on the <i>In Vivo</i> Performance of Oral Formulations Containing N-Acetylcysteine: An <i>In Vitro</i> Approach Using the Dynamic Open Flow-Through Test Apparatus. Molecular Pharmaceutics, 2017, 14, 4272-4280.	2.3	9
61	In vitro dissolution testing of parenteral aqueous solutions and oily suspensions of paracetamol and prednisolone. International Journal of Pharmaceutics, 2017, 532, 519-527.	2.6	8
62	Distribution of fluorescein sodium and triamcinolone acetonide in the simulated liquefied and vitrectomized Vitreous Model with simulated eye movements. European Journal of Pharmaceutical Sciences, 2017, 109, 233-243.	1.9	9
63	Gastric Water Emptying under Fed State Clinical Trial Conditions Is as Fast as under Fasted Conditions. Molecular Pharmaceutics, 2017, 14, 4262-4271.	2.3	63
64	A novel mechanical antrum model for the prediction of the gastroretentive potential of dosage forms. International Journal of Pharmaceutics, 2017, 530, 63-70.	2.6	12
65	Measurement of abomasal conditions (pH, pressure and temperature) in healthy and diarrheic dairy calves using a wireless ambulatory capsule. Livestock Science, 2017, 203, 41-47.	0.6	6
66	In vitro simulation of realistic gastric pressure profiles. European Journal of Pharmaceutical Sciences, 2017, 107, 71-77.	1.9	25
67	Glycerol gelatin for 3D-printing of implants using a paste extrusion technique. Current Directions in Biomedical Engineering, 2017, 3, 389-392.	0.2	3
68	Gastroresistant gelatin films prepared by addition of cellulose acetate phthalate. Die Pharmazie, 2017, 72, 324-328.	0.3	7
69	Influence of Siluron $\hat{A}^{@}$ insertion on model drug distribution in the simulated vitreous body. Current Directions in Biomedical Engineering, 2016, 2, 665-668.	0.2	1
70	Extendedâ€release but not immediateâ€release and subcutaneous methylnaltrexone antagonizes the loperamideâ€rnduced delay of wholeâ€gut transit time in healthy subjects. Journal of Clinical Pharmacology, 2016, 56, 239-245.	1.0	17
71	Trospium chloride is absorbed from two intestinal "absorption windows―with different permeability in healthy subjects. International Journal of Pharmaceutics, 2016, 515, 367-373.	2.6	14
72	Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Gut, 2016, 65, 1838-1849.	6.1	71

#	Article	IF	Citations
73	Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers. Advanced Drug Delivery Reviews, 2016, 101, 75-88.	6.6	125
74	Simultaneous magnetic resonance imaging and pharmacokinetic analysis of intramuscular depots. Journal of Controlled Release, 2016, 227, 1-12.	4.8	15
75	Pharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine model. Experimental Animals, 2016, 65, 147-155.	0.7	12
76	Resolving the physiological conditions in bioavailability and bioequivalence studies: Comparison of fasted and fed state. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 214-219.	2.0	71
77	<i>In vitro</i> simulation of distribution processes following intramuscular injection. Current Directions in Biomedical Engineering, 2016, 2, 383-386.	0.2	0
78	Rapid Tolerance to Constipating Effects of Loperamide in Healthy Subjects. Journal of Clinical Pharmacology, 2016, 56, 248-249.	1.0	3
79	Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions. Pharmaceutical Research, 2016, 33, 751-762.	1.7	13
80	MR imaging of model drug distribution in simulated vitreous. Current Directions in Biomedical Engineering, 2015, 1, 236-239.	0.2	2
81	Targeted adsorption of molecules in the colon with the novel adsorbentâ€based Medicinal Product, DAV132: A proof of concept study in healthy subjects. Journal of Clinical Pharmacology, 2015, 55, 10-16.	1.0	57
82	Controlling drug delivery from coronary stents: are we aiming for the right targets?. Therapeutic Delivery, 2015, 6, 705-720.	1.2	5
83	Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions. Journal of Pharmacy and Pharmacology, 2015, 67, 199-208.	1.2	20
84	Bioequivalence of Sandoz methylphenidate osmoticâ€controlled release tablet with Concerta <sup>®</sup> (Janssenâ€Cilag). Pharmacology Research and Perspectives, 2015, 3, e00072.	1.1	8
85	Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 155-170.	2.0	47
86	In vitro study of sirolimus release from a drug-eluting stent: Comparison of the release profiles obtained using different test setups. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 328-338.	2.0	21
87	Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies. Journal of Controlled Release, 2015, 220, 71-78.	4.8	129
88	In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 322-328.	2.0	31
89	Design, development and <i>in-vitro </i> evaluation of diclofenac taste-masked orodispersible tablet formulations. Drug Development and Industrial Pharmacy, 2015, 41, 540-551.	0.9	38
90	Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap® System. Journal of Pharmaceutical Sciences, 2015, 104, 2855-2863.	1.6	324

#	Article	IF	CITATIONS
91	Simulation of Drug Distribution in the Vitreous Body After Local Drug Application into Intact Vitreous Body and in Progress of Posterior Vitreous Detachment. Journal of Pharmaceutical Sciences, 2014, 103, 517-526.	1.6	19
92	Characterization of the Intestinal and Hepatic Uptake/Efflux Transport of the Magnetic Resonance Imaging Contrast Agent Gadolinium-Ethoxylbenzyl-Diethylenetriamine-Pentaacetic Acid. Investigative Radiology, 2014, 49, 78-86.	3.5	43
93	PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 300-321.	1.9	263
94	In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 342-366.	1.9	297
95	Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach. European Journal of Pharmaceutical Sciences, 2014, 57, 250-256.	1.9	47
96	In vivo methods for drug absorption $\hat{a} \in Comparative$ physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	1.9	226
97	Development of pressure-sensitive dosage forms with a core liquefying at body temperature. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 507-513.	2.0	7
98	Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus. European Journal of Pharmaceutical Sciences, 2014, 57, 264-272.	1.9	29
99	Development of a pressure-sensitive glyceryl tristearate capsule filled with a drug-containing hydrogel. International Journal of Pharmaceutics, 2014, 461, 296-300.	2.6	16
100	Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions. AAPS PharmSciTech, 2014, 15, 230-236.	1.5	26
101	A standardised static <i>in vitro</i> digestion method suitable for food – an international consensus. Food and Function, 2014, 5, 1113-1124.	2.1	3,730
102	Intragastric Volume Changes after Intake of a High-Caloric, High-Fat Standard Breakfast in Healthy Human Subjects Investigated by MRI. Molecular Pharmaceutics, 2014, 11, 1632-1639.	2.3	92
103	Feasibility of gadoxetate disodium-enhanced MR cholangiography in chronic cholestatic biliary disease. Clinical Radiology, 2014, 69, 1027-1033.	0.5	1
104	Oral biopharmaceutics tools $\hat{a} \in \text{``Iime for a new initiative } \hat{a} \in \text{``An introduction to the IMI project OrBiTo.}$ European Journal of Pharmaceutical Sciences, 2014, 57, 292-299.	1.9	91
105	The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets. Journal of Controlled Release, 2014, 187, 50-58.	4.8	70
106	Impact of different tissue-simulating hydrogel compartments on in vitro release and distribution from drug-eluting stents. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 570-578.	2.0	11
107	A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds. European Journal of Pharmaceutical Sciences, 2014, 51, 224-231.	1.9	60
108	Binding of anti–platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood, 2014, 124, 2442-2449.	0.6	67

#	Article	IF	Citations
109	An Automated System for Monitoring and Regulating the pH of Bicarbonate Buffers. AAPS PharmSciTech, 2013, 14, 517-522.	1.5	40
110	Development of Hydrophobized Alginate Hydrogels for the Vessel-Simulating Flow-Through Cell and Their Usage for Biorelevant Drug-Eluting Stent Testing. AAPS PharmSciTech, 2013, 14, 1209-1218.	1.5	18
111	Oral Anticancer Drugs: Back to Square One. Clinical Pharmacology and Therapeutics, 2013, 94, 441-442.	2.3	5
112	Changes in recovery due to drug product matrix ageing as a source of mass imbalances. Journal of Pharmaceutical and Biomedical Analysis, 2013, 74, 117-125.	1.4	4
113	The role of individual gastric emptying of pellets in the prediction of diclofenac in vivo dissolution. Journal of Controlled Release, 2013, 166, 286-293.	4.8	16
114	Design of Biorelevant Test Setups for the Prediction of Diclofenac In Vivo Features After Oral Administration. Pharmaceutical Research, 2013, 30, 1483-1501.	1.7	22
115	Simulating the Postprandial Stomach: Biorelevant Test Methods for the Estimation of Intragastric Drug Dissolution. Molecular Pharmaceutics, 2013, 10, 2211-2221.	2.3	43
116	Simulating the Postprandial Stomach: Physiological Considerations for Dissolution and Release Testing. Molecular Pharmaceutics, 2013, 10, 1610-1622.	2.3	76
117	Advances in Coronary Stent Technology - Active Drug-Loaded Stent Surfaces for Prevention of Restenosis and Improvement of Biocompatibility. Current Pharmaceutical Biotechnology, 2013, 14, 76-90.	0.9	0
118	In Vitro Dissolution Testing of Drug-Eluting Stents. Current Pharmaceutical Biotechnology, 2013, 14, 67-75.	0.9	7
119	Simulation of the Conjunctival and Choroidal Blood Flow Using a New Multi-Layer Diffusion Cell. Biomedizinische Technik, $2013,58$ Suppl $1,.$	0.9	1
120	In Vitro Determination of Drug Transfer from Drug-Coated Balloons. PLoS ONE, 2013, 8, e83992.	1.1	35
121	Advances in Coronary Stent Technology - Active Drug-Loaded Stent Surfaces for Prevention of Restenosis and Improvement of Biocompatibility. Current Pharmaceutical Biotechnology, 2013, 14, 76-90.	0.9	11
122	Long-term stable hydrogels for biorelevant dissolution testing of drug-eluting stents. Journal of Pharmaceutical Technology & Drug Research, 2013, 2, 19.	1.0	12
123	In vitro dissolution testing of drug-eluting stents. Current Pharmaceutical Biotechnology, 2013, 14, 67-75.	0.9	9
124	Advances in coronary stent technology-active drug-loaded stent surfaces for prevention of restenosis and improvement of biocompatibility. Current Pharmaceutical Biotechnology, 2013, 14, 76-90.	0.9	16
125	Response. Radiology, 2013, 267, 315.	3.6	0
126	Visualization of Hepatic Uptake Transporter Function in Healthy Subjects by Using Gadoxetic Acid–enhanced MR Imaging. Radiology, 2012, 264, 741-750.	3.6	123

#	Article	IF	Citations
127	In vitro estimation of drug loss during the implantation procedure of drug-eluting stents. Biomedizinische Technik, 2012, 57, .	0.9	3
128	The Vitreous Model $\hat{a} \in \hat{a}$ a new in vitro test method simulating the vitreous body. Biomedizinische Technik, 2012, 57, .	0.9	13
129	Development of oral taste masked diclofenac formulations using a taste sensing system. International Journal of Pharmaceutics, 2012, 438, 81-90.	2.6	57
130	Development of a method for magnetic labeling of platelets. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 537-544.	1.7	24
131	A novel liquefied gas based oral controlled release drug delivery system for liquid drug formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 334-338.	2.0	7
132	Coating of collars via fluidised-bed process. Biomedizinische Technik, 2012, 57, .	0.9	0
133	Examination of steroid release from screw-in pacing leads. Biomedizinische Technik, 2012, 57, .	0.9	1
134	Implant-associated local drug delivery systems for different medical applications. Biomedizinische Technik, 2012, 57, .	0.9	1
135	Preparation and characterization of magnetizable aerosols. European Journal of Pharmaceutical Sciences, 2012, 45, 693-697.	1.9	14
136	Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes. European Journal of Pharmaceutical Sciences, 2012, 47, 131-138.	1.9	80
137	In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. Journal of Pharmacy and Pharmacology, 2012, 64, 969-985.	1.2	33
138	Foreword for the JPP special issue †Recent Innovations in Dissolution Testing'. Journal of Pharmacy and Pharmacology, 2012, 64, 909-910.	1.2	1
139	Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells <i>in vitro</i> . Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2012, 100B, 41-50.	1.6	50
140	A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations. Pharmaceutical Research, 2012, 29, 695-706.	1.7	18
141	A Semi-mechanistic Modeling Strategy for Characterization of Regional Absorption Properties and Prospective Prediction of Plasma Concentrations Following Administration of New Modified Release Formulations. Pharmaceutical Research, 2012, 29, 574-584.	1.7	16
142	Biodegradable Sirolimus-loaded Poly(lactide) Nanoparticles as Drug Delivery System for the Prevention of In-Stent Restenosis in Coronary Stent Application. Journal of Biomaterials Applications, 2011, 25, 851-875.	1.2	56
143	Direct Visualization and Identification of Biofunctionalized Nanoparticles using a Magnetic Atomic Force Microscope. Nano Letters, 2011, 11, 3587-3592.	4.5	18
144	Examination of drug release and distribution from drug-eluting stents with a vessel-simulating flow-through cell. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 36-48.	2.0	38

#	Article	IF	CITATIONS
145	Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 166-172.	2.0	70
146	An Oral-Controlled Release Drug Delivery System for Liquid and Semisolid Drug Formulations. AAPS PharmSciTech, 2011, 12, 1183-1185.	1.5	4
147	Drug Interactions Between the Immunosuppressant Tacrolimus and the Cholesterol Absorption Inhibitor Ezetimibe in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2011, 89, 524-528.	2.3	13
148	In vivo imaging of drug delivery systems in the gastrointestinal tract. International Journal of Pharmaceutics, 2011, 417, 216-226.	2.6	50
149	Investigation of magnetic active core sizes and hydrodynamic diameters of a magnetically fractionated ferrofluid. Journal of Nanoparticle Research, 2011, 13, 165-173.	0.8	6
150	An International Network for Improving Health Properties of Food by Sharing our Knowledge on the Digestive Process. Food Digestion, 2011, 2, 23-25.	0.9	24
151	Investigating the Stability of the Nonionic Surfactants Tocopheryl Polyethylene glycol Succinate and Sucrose Laurate by HPLC–MS, DAD, and CAD. Journal of Pharmaceutical Sciences, 2011, 100, 1773-1782.	1.6	17
152	Biorelevant Dissolution Testing of Drug-Eluting Stents: Experiences with a Modified Flow-Through Cell Setup. Dissolution Technologies, 2011, 18, 26-35.	0.2	13
153	Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 381, 161-169.	1.4	36
154	N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. European Journal of Pharmaceutical Sciences, 2010, 41, 201-209.	1.9	33
155	Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. European Journal of Pharmaceutical Sciences, 2010, 41, 376-382.	1.9	82
156	Pharmacokinetic and Pharmacodynamic Interactions Between the Immunosuppressant Sirolimus and the Lipid-Lowering Drug Ezetimibe in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2010, 87, 663-667.	2.3	22
157	Drug Delivery in the GI Tract: How Controlled is Controlled Release?. Scientia Pharmaceutica, 2010, 78, 541-541.	0.7	0
158	Hepatic Uptake of the Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA: Role of Human Organic Anion Transporters. Drug Metabolism and Disposition, 2010, 38, 1024-1028.	1.7	210
159	Investigation of Magnetically Active Core Size Distributions Utilizing Magnetic Measurements. , 2010, , .		0
160	Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditions. Drug Development and Industrial Pharmacy, 2010, 36, 518-530.	0.9	23
161	A biorelevant dissolution stress test device – background and experiences. Expert Opinion on Drug Delivery, 2010, 7, 1251-1261.	2.4	62
162	Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 84-92.	2.0	45

#	Article	IF	CITATIONS
163	Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 93-101.	2.0	118
164	Adhesion testing of transdermal matrix patches with a probe tack test $\hat{a} \in \text{``In vitro and in vivo}$ evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 399-404.	2.0	32
165	Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 260-268.	2.0	81
166	Magneto-Optical Relaxation Measurements of Functionalized Nanoparticles as a Novel Biosensor. Sensors, 2009, 9, 4022-4033.	2.1	5
167	Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses. European Journal of Pharmaceutical Sciences, 2009, 38, 147-155.	1.9	62
168	Mechanistic Modeling of a Magnetic Marker Monitoring Study Linking Gastrointestinal Tablet Transit, In Vivo Drug Release, and Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2009, 86, 77-83.	2.3	27
169	Investigation of the Dissolution Characteristics of Nifedipine Extended-Release Formulations Using USP Apparatus 2 and a Novel Dissolution Apparatus. Dissolution Technologies, 2009, 16, 6-13.	0.2	8
170	Characterization of the behavior of alginate-based microcapsules in vitro and in vivo. International Journal of Clinical Pharmacology and Therapeutics, 2009, 47, 556-563.	0.3	5
171	Heparinâ€induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes. Journal of Thrombosis and Haemostasis, 2008, 6, 2160-2167.	1.9	68
172	Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. Journal of Controlled Release, 2008, 130, 2-8.	4.8	44
173	Development of an oral vaccine for immunisation of rainbow trout (Oncorhynchus mykiss) against viral haemorrhagic septicaemia. Vaccine, 2008, 26, 837-844.	1.7	92
174	Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thrombosis Research, 2008, 122, 211-220.	0.8	105
175	Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 641-648.	2.0	57
176	Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 421-428.	2.0	145
177	Affinity analysis for biomolecular interactions based on magneto-optical relaxation measurements. Nanotechnology, 2008, 19, 505102.	1.3	8
178	Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadianâ€√Time Rhythms. Journal of Clinical Pharmacology, 2008, 48, 570-579.	1.0	15
179	Energy barrier distributions of maghemite nanoparticles. Nanotechnology, 2007, 18, 115709.	1.3	13
180	Evaluation of Consultation in Community Pharmacies with Mystery Shoppers. Annals of Pharmacotherapy, 2007, 41, 1023-1030.	0.9	57

#	Article	IF	CITATIONS
181	Determination of the Magneto-Optical Relaxation of Magnetic Nanoparticles as a Homogeneous Immunoassay. Analytical Chemistry, 2007, 79, 580-586.	3.2	43
182	Polyaspartate coated magnetite nanoparticles for biomedical applications. Journal of Magnetism and Magnetic Materials, $2007, 311, 1-5$ .	1.0	31
183	Characterization of energy barrier and particle size distribution of lyophilized ferrofluids by magnetic relaxation measurements. Journal of Magnetism and Magnetic Materials, 2007, 311, 171-175.	1.0	8
184	The effect of field parameters, nanoparticle properties and immobilization on the specific heating power in magnetic particle hyperthermia. Journal of Physics Condensed Matter, 2006, 18, S2935-S2949.	0.7	136
185	Magneto-optical relaxation measurements for the characterization of biomolecular interactions. Journal of Physics Condensed Matter, 2006, 18, S2847-S2863.	0.7	14
186	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 206-217.	2.3	94
187	Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical Pharmacology and Therapeutics, 2006, 80, 477-485.	2.3	41
188	Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells. Journal of Cancer Research and Clinical Oncology, 2006, 132, 287-292.	1.2	50
189	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2386-2393.	1.1	156
190	Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1293-1299.	1.3	31
191	Magnetic Marker Monitoring: An application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Advanced Drug Delivery Reviews, 2005, 57, 1210-1222.	6.6	119
192	Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2005, 22, 971-979.	1.9	522
193	Impact of the intragastric location of extended release tablets on food interactions. Journal of Controlled Release, 2005, 108, 375-385.	4.8	115
194	Development of a liquid phase immunoassay by time-dependent measurements of the transient magneto-optical birefringence using functionalized magnetic nanoparticles. Journal of Magnetism and Magnetic Materials, 2005, 289, 480-483.	1.0	24
195	The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen. Pharmaceutical Research, 2005, 22, 728-735.	1.7	58
196	Magnetic nanoparticles for selective heating of magnetically labelled cells in culture: preliminary investigation. Nanotechnology, 2004, 15, 1027-1032.	1.3	63
197	Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. Neurogastroenterology and Motility, 2004, 16, 547-556.	1.6	43
198	Enhancement of AC-losses of magnetic nanoparticles for heating applications. Journal of Magnetism and Magnetic Materials, 2004, 280, 358-368.	1.0	182

#	Article	IF	Citations
199	CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clinical Pharmacology and Therapeutics, 2004, 75, 213-222.	2.3	118
200	Nanoparticle Composition of a Ferrofluid and Its Effects on the Magnetic Properties. Langmuir, 2004, 20, 2435-2444.	1.6	52
201	Variability of Intestinal Expression of P-Glycoprotein in Healthy Volunteers as Described by Absorption of Talinolol from Four Bioequivalent Tablets. Journal of Pharmaceutical Sciences, 2003, 92, 604-610.	1.6	33
202	Determination of energy barrier distributions of magnetic nanoparticles by temperature dependent magnetorelaxometry. Nanotechnology, 2003, 14, 1251-1254.	1.3	26
203	INVESTIGATION OF GASTROINTESTINAL TRANSPORT BY MAGNETIC MARKER LOCALIZATION. Biomedizinische Technik, 2002, 47, 506-509.	0.9	7
204	Bursting and spreading of liposomes on the surface of a static mercury drop electrode. Electrochemistry Communications, 2002, 4, 305-309.	2.3	103
205	Determination of biological binding reactions by field-induced birefringence measurements. Journal of Magnetism and Magnetic Materials, 2002, 252, 384-386.	1.0	18
206	Magnetic nanoparticle relaxation measurement as a novel tool for in vivo diagnostics. Journal of Magnetism and Magnetic Materials, 2002, 252, 387-389.	1.0	56
207	Magnetorelaxometry—a new binding specific detection method based on magnetic nanoparticles. Journal of Magnetism and Magnetic Materials, 2002, 252, 381-383.	1.0	76
208	Determination of the disintegration behavior of magnetically marked tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 52, 221-226.	2.0	18
209	Magnetic marker monitoring of disintegrating capsules. European Journal of Pharmaceutical Sciences, 2001, 13, 411-416.	1.9	61
210	Comparison of size-selective techniques for the fractionation of magnetic fluids. Journal of Magnetism and Magnetic Materials, 2000, 214, 269-275.	1.0	22
211	Magnetic fractionation of magnetic fluids. Journal of Magnetism and Magnetic Materials, 2000, 219, 219-228.	1.0	53
212	Different methods for the fractionation of magnetic fluids. Colloid and Polymer Science, 2000, 278, 259-263.	1.0	14
213	Magnetic Fluids: Biomedical Applications and Magnetic Fractionation. Magnetic & Electrical Separation, 2000, 10, 179-199.	0.5	5
214	LTS SQUID gradiometer system for in vivo magnetorelaxometry. Superconductor Science and Technology, 1999, 12, 953-955.	1.8	12
215	Magnetic nanoparticle relaxation measured by a low-TcSQUID system. Superconductor Science and Technology, 1999, 12, 956-958.	1.8	19
216	SQUID gradiometer measurement system for magnetorelaxometry in a disturbed environment. IEEE Transactions on Applied Superconductivity, 1999, 9, 3527-3530.	1.1	11

#	Article	lF	CITATIONS
217	Dynamic properties of fractions yielded by magnetic fractionation of magnetic fluids. IEEE Transactions on Magnetics, 1999, 35, 4055-4057.	1.2	9
218	A SQUID measurement system for immunoassays. Applied Superconductivity, 1999, 6, 577-583.	0.5	64
219	Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles. Journal of Magnetism and Magnetic Materials, 1999, 194, 62-68.	1.0	134
220	Investigation of Brownian and NÃ $\otimes$ el relaxation in magnetic fluids. Journal of Magnetism and Magnetic Materials, 1999, 201, 102-104.	1.0	70
221	Magnetic marker monitoring of esophageal, gastric and duodenal transit of non-disintegrating capsules. Die Pharmazie, 1999, 54, 426-30.	0.3	30
222	SQUID based remanence measurements for immunoassays. IEEE Transactions on Applied Superconductivity, 1997, 7, 3678-3681.	1.1	129
223	High-Resolution Monitoring of the Gastrointestinal Transit of a Magnetically Marked Capsule. Journal of Pharmaceutical Sciences, 1997, 86, 1218-1222.	1.6	70
224	Delineation of Experimental Liver Tumors in Rabbits by a New Ultrasound Contrast Agent and Stimulated Acoustic Emission. Investigative Radiology, 1997, 32, 94-99.	3.5	68
225	Magnetic markers as a noninvasive tool to monitor gastrointestinal transit. IEEE Transactions on Biomedical Engineering, 1994, 41, 192-195.	2.5	64